• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过分子对接研究细胞色素P450(CYP)3A4对帕唑帕尼的代谢行为预测

Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking.

作者信息

Liu Xing-Jie, Lu Hua, Sun Ju-Xiang, Wang Su-Rong, Mo Yan-Shuai, Yang Xing-Sheng, Shi Ben-Kang

机构信息

Qilu Hospital of Shandong University, Jinan, Shandong, China.

Linyi People's Hospital, Linyi, Shandong, China.

出版信息

Eur J Drug Metab Pharmacokinet. 2016 Aug;41(4):465-8. doi: 10.1007/s13318-015-0252-y. Epub 2015 Mar 4.

DOI:10.1007/s13318-015-0252-y
PMID:25737032
Abstract

Metabolism-mediated drug adverse effects (e.g., drug-drug interaction, bioactivation, etc.) strongly limit the utilization of clinical drugs. The present study aims to predict the metabolic capability of cytochrome P450 (CYP) 3A4 toward pazopanib which is an excellent drug exhibiting therapeutic role toward various cancers especially for ovarian cancer. Pazopanib can be well docked into the activity cavity of CYP3A4, and the interaction structure in pazopanib was methyl group located besides nitrogen in the five-membered ring. The distance between the hydrogen atom in methyl group and active center is 3.64 Å. The interaction amino acid is Glu374. Furthermore, both pazopanib and ketoconazole were docked into the activity cavity of CYP3A4 to compare their binding potential. The distance between ketoconazole and activity center (2.10 Å) is closer than the distance between pazopanib and activity center of CYP3A4, indicating the easy influence of CYP3A4 inhibitor toward the metabolism of pazopanib. All these data were helpful for the clinical application of pazopanib, and R&D of other tinib drug candidates as new anti-tumor drugs.

摘要

代谢介导的药物不良反应(如药物相互作用、生物活化等)严重限制了临床药物的应用。本研究旨在预测细胞色素P450(CYP)3A4对帕唑帕尼的代谢能力,帕唑帕尼是一种对多种癌症尤其是卵巢癌具有治疗作用的优秀药物。帕唑帕尼能够很好地对接至CYP3A4的活性腔中,其在帕唑帕尼中的相互作用结构是五元环中氮旁边的甲基。甲基中的氢原子与活性中心的距离为3.64 Å。相互作用的氨基酸是Glu374。此外,将帕唑帕尼和酮康唑都对接至CYP3A4的活性腔中以比较它们的结合潜力。酮康唑与活性中心的距离(2.10 Å)比帕唑帕尼与CYP3A4活性中心的距离更近,表明CYP3A4抑制剂对帕唑帕尼代谢的影响较大。所有这些数据有助于帕唑帕尼的临床应用以及其他替尼类候选药物作为新型抗肿瘤药物的研发。

相似文献

1
Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking.通过分子对接研究细胞色素P450(CYP)3A4对帕唑帕尼的代谢行为预测
Eur J Drug Metab Pharmacokinet. 2016 Aug;41(4):465-8. doi: 10.1007/s13318-015-0252-y. Epub 2015 Mar 4.
2
Drug-drug interation prediction between ketoconazole and anti-liver cancer drug Gomisin G.酮康唑与抗肝癌药物五味子酯G之间的药物相互作用预测
Afr Health Sci. 2015 Jun;15(2):590-3. doi: 10.4314/ahs.v15i2.35.
3
Molecular docking to understand the metabolic behavior of GNF-351 by CYP3A4 and its potential drug-drug interaction with ketoconazole.通过CYP3A4进行分子对接以了解GNF-351的代谢行为及其与酮康唑的潜在药物相互作用。
Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):235-8. doi: 10.1007/s13318-014-0201-1. Epub 2014 Apr 23.
4
General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.基于标准药物联合给药后AUC增加的CYP3A4介导的口服药物相互作用定量预测的一般框架。
Clin Pharmacokinet. 2007;46(8):681-96. doi: 10.2165/00003088-200746080-00005.
5
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.酮康唑和埃索美拉唑对固体肿瘤患者帕唑帕尼药代动力学的影响。
Cancer Chemother Pharmacol. 2013 Jun;71(6):1635-43. doi: 10.1007/s00280-013-2164-3. Epub 2013 May 1.
6
A Combined Molecular Docking/Dynamics Approach to Probe the Binding Mode of Cancer Drugs with Cytochrome P450 3A4.一种结合分子对接/动力学的方法来探究癌症药物与细胞色素P450 3A4的结合模式。
Molecules. 2015 Aug 14;20(8):14915-35. doi: 10.3390/molecules200814915.
7
Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.对硫磷在人肝脏中的生物转化:CYP3A4的参与及其在微粒体对硫磷氧化过程中的失活
J Pharmacol Exp Ther. 1997 Feb;280(2):966-73.
8
Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors.氯氮平生物转化途径在人肝微粒体中对 CYP1A2 和 CYP3A4 选择性抑制剂反应的差异。
Basic Clin Pharmacol Toxicol. 2018 Apr;122(4):388-395. doi: 10.1111/bcpt.12933. Epub 2017 Dec 15.
9
Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates.酮康唑对细胞色素P450 3A4(CYP3A4)抑制作用的对映体选择性:以睾酮和美沙酮作为底物
Chirality. 2004 Feb;16(2):79-85. doi: 10.1002/chir.10294.
10
Enzyme Kinetics and Molecular Docking Studies on Cytochrome 2B6, 2C19, 2E1, and 3A4 Activities by Sauchinone.姜酮对细胞色素 2B6、2C19、2E1 和 3A4 活性的酶动力学和分子对接研究。
Molecules. 2018 Mar 2;23(3):555. doi: 10.3390/molecules23030555.

引用本文的文献

1
Comparative Study of Binding Behaviors of Cyanidin, Cyanidin-3-Galactoside, Peonidin with Tyrosinase.花青素、矢车菊素-3-半乳糖苷、芍药素与酪氨酸酶结合行为的比较研究。
J Fluoresc. 2024 Jul;34(4):1747-1760. doi: 10.1007/s10895-023-03384-z. Epub 2023 Aug 21.
2
Interaction between phytotherapy and oral anticancer agents: prospective study and literature review.草药疗法与口服抗癌药物的相互作用:前瞻性研究和文献回顾。
Med Oncol. 2019 Apr 16;36(5):45. doi: 10.1007/s12032-019-1267-z.
3
Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.

本文引用的文献

1
Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer.节拍式口服紫杉醇在卵巢癌原位模型小鼠中显示出抗肿瘤作用。
J Gynecol Oncol. 2014 Apr;25(2):130-5. doi: 10.3802/jgo.2014.25.2.130. Epub 2014 Apr 9.
2
Molecular docking to understand the metabolic behavior of GNF-351 by CYP3A4 and its potential drug-drug interaction with ketoconazole.通过CYP3A4进行分子对接以了解GNF-351的代谢行为及其与酮康唑的潜在药物相互作用。
Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):235-8. doi: 10.1007/s13318-014-0201-1. Epub 2014 Apr 23.
3
The role of Rho GTPase in cell stiffness and cisplatin resistance in ovarian cancer cells.
帕唑帕尼,一种新型多激酶抑制剂,通过PUMA介导的凋亡在结肠癌中显示出强大的抗肿瘤活性。
Oncotarget. 2017 Jan 10;8(2):3289-3303. doi: 10.18632/oncotarget.13753.
Rho GTP酶在卵巢癌细胞的细胞硬度和顺铂耐药性中的作用。
Integr Biol (Camb). 2014 Jun;6(6):611-7. doi: 10.1039/c3ib40246k.
4
Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.帕唑帕尼概况及其在治疗上皮性卵巢癌中的潜力。
Int J Womens Health. 2014 Mar 13;6:289-300. doi: 10.2147/IJWH.S49781. eCollection 2014.
5
Herb-drug interaction prediction based on the high specific inhibition of andrographolide derivatives towards UDP-glucuronosyltransferase (UGT) 2B7.基于穿心莲内酯衍生物对 UDP-葡糖醛酸基转移酶(UGT)2B7 的高特异性抑制作用预测草药-药物相互作用。
Toxicol Appl Pharmacol. 2014 May 15;277(1):86-94. doi: 10.1016/j.taap.2014.02.021. Epub 2014 Mar 12.
6
Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells.卵巢癌细胞中微小RNA表达特征差异及与紫杉醇耐药性的细胞类型特异性关联
Drug Des Devel Ther. 2014 Feb 24;8:293-314. doi: 10.2147/DDDT.S51969. eCollection 2014.
7
Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4.氟西汀和去甲氟西汀介导的复杂药物相互作用:对 CYP2D6、CYP2C19 和 CYP3A4 影响的体外到体内相关性。
Clin Pharmacol Ther. 2014 Jun;95(6):653-62. doi: 10.1038/clpt.2014.50. Epub 2014 Feb 25.
8
Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer.基于药物基因组学评估卵巢癌顺铂化疗的结局。
Pharmacogenomics. 2014 Feb;15(3):329-37. doi: 10.2217/pgs.13.237.
9
The multikinase inhibitor axitinib is a potent inhibitor of human CYP1A2.多激酶抑制剂阿昔替尼是人细胞色素 CYP1A2 的强效抑制剂。
Biochem Pharmacol. 2014 Mar 15;88(2):245-52. doi: 10.1016/j.bcp.2014.01.016. Epub 2014 Jan 22.
10
A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer.一项奥沙利铂联合拓扑替康持续输注治疗既往治疗的卵巢癌患者的 II 期研究。
Int J Gynecol Cancer. 2013 Nov;23(9):1577-82. doi: 10.1097/IGC.0b013e3182a809e0.